Recent discoveries concerning the tumor - mesenchymal stem cell interactions

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1866, Issue 2, 2016, Pages 290-299

  Gwendal, Lazennec ^a   Paula Y, Lam ^b,c,d  

^a CNRS   (France)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Chemokines; Cytokines; Mesenchymal stem cells; Tumor microenvironment

Indexed keywords

ANGIOGENESIS; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER LOCALIZATION; CANCER STEM CELL; CARCINOGENESIS; CELL DEATH; CELL FUNCTION; CELL INTERACTION; CELL INVASION; CELL METABOLISM; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MESENCHYMAL STEM CELL; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ANIMAL; APOPTOSIS; CELL COMMUNICATION; MESENCHYMAL STROMA CELL; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; CANCER-ASSOCIATED FIBROBLASTS; CELL COMMUNICATION; CELL PROLIFERATION; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84992691648     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.10.004     Document Type: Review

References (100)

1. [1] Lazennec, G., Jorgensen, C., Concise review: adult multipotent stromal cells and cancer: risk or benefit?. Stem Cells 26 (2008), 1387–1394.
2. [2] Niess, H., von Einem, J.C., Thomas, M.N., Michl, M., Angele, M.K., Huss, R., Gunther, C., Nelson, P.J., Bruns, C.J., Heinemann, V., Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. BMC Cancer, 15, 2015, 237.
3. [3] Karnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W., Richardson, A.L., Polyak, K., Tubo, R., Weinberg, R.A., Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007), 557–563.
4. [4] Chavey, C., Bibeau, F., Gourgou-Bourgade, S., Burlinchon, S., Boissiere, F., Laune, D., Roques, S., Lazennec, G., Estrogen-receptor negative breast cancers exhibit a high cytokine content. Breast Cancer Res., 9, 2007, R15.
5. [5] Lazennec, G., Richmond, A., Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 16 (2010), 133–144.
6. [6] Boissiere-Michot, F., Lazennec, G., Frugier, H., Jarlier, M., Roca, L., Duffour, J., Paty, E.D., Laune, D., Blanchard, F., Le Pessot, F., Sabourin, J.C., Bibeau, F., Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology, 3, 2014, e29256.
7. [7] Klopp, A.H., Spaeth, E.L., Dembinski, J.L., Woodward, W.A., Munshi, A., Meyn, R.E., Cox, J.D., Andreeff, M., Marini, F.C., Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 67 (2007), 11687–11695.
8. [8] Menon, L.G., Picinich, S., Koneru, R., Gao, H., Lin, S.Y., Koneru, M., Mayer-Kuckuk, P., Glod, J., Banerjee, D., Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 25 (2007), 520–528.
9. [9] Kim, D.S., Kim, J.H., Lee, J.K., Choi, S.J., Kim, J.S., Jeun, S.S., Oh, W., Yang, Y.S., Chang, J.W., Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev. 18 (2009), 511–519.
10. [10] Dwyer, R.M., Potter-Beirne, S.M., Harrington, K.A., Lowery, A.J., Hennessy, E., Murphy, J.M., Barry, F.P., O'Brien, T., Kerin, M.J., Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res. 13 (2007), 5020–5027.
11. [11] Xu, S., Menu, E., De Becker, A., Van Camp, B., Vanderkerken, K., Van Riet, I., Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 30 (2012), 266–279.
12. [12] Lejmi, E., Perriraz, N., Clement, S., Morel, P., Baertschiger, R., Christofilopoulos, P., Meier, R., Bosco, D., Buhler, L.H., Gonelle-Gispert, C., Inflammatory chemokines MIP-1delta and MIP-3alpha are involved in the migration of multipotent mesenchymal stromal cells induced by hepatoma cells. Stem Cells Dev. 24 (2015), 1223–1235.
13. [13] Lourenco, S., Teixeira, V.H., Kalber, T., Jose, R.J., Floto, R.A., Janes, S.M., Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J. Immunol. 194 (2015), 3463–3474.
14. [14] Haga, H., Yan, I.K., Takahashi, K., Wood, J., Zubair, A., Patel, T., Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J. Extracell. Vesicles, 4, 2015, 24900.
15. [15] Coffelt, S.B., Marini, F.C., Watson, K., Zwezdaryk, K.J., Dembinski, J.L., LaMarca, H.L., Tomchuck, S.L., Bentrup, K.H.z., Danka, E.S., Henkle, S.L., Scandurro, A.B., The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 3806–3811.
16. [16] Lin, S.Y., Yang, J., Everett, A.D., Clevenger, C.V., Koneru, M., Mishra, P.J., Kamen, B., Banerjee, D., Glod, J., The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp. Cell Res. 314 (2008), 3107–3117.
17. [17] Birnbaum, T., Roider, J., Schankin, C.J., Padovan, C.S., Schichor, C., Goldbrunner, R., Straube, A., Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J. Neuro. Oncol. 83 (2007), 241–247.
18. [18] Gutova, M., Najbauer, J., Frank, R.T., Kendall, S.E., Gevorgyan, A., Metz, M.Z., Guevorkian, M., Edmiston, M., Zhao, D., Glackin, C.A., Kim, S.U., Aboody, K.S., Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26 (2008), 1406–1413.
19. [19] Heissig, B., Dhahri, D., Eiamboonsert, S., Salama, Y., Shimazu, H., Munakata, S., Hattori, K., Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. Cell. Mol. Life Sci. 72 (2015), 4759–4770.
20. [20] Ho, I.A., Yulyana, Y., Sia, K.C., Newman, J.P., Guo, C.M., Hui, K.M., Lam, P.Y., Matrix metalloproteinase-1-mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis. FASEB J. 28 (2014), 4359–4368.
21. [21] Ho, I.A., Chan, K.Y., Ng, W.H., Guo, C.M., Hui, K.M., Cheang, P., Lam, P.Y., Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27 (2009), 1366–1375.
22. [22] Zheng, Y., He, L., Wan, Y., Song, J., H3K9me-enhanced DNA hypermethylation of the p16INK4a gene: an epigenetic signature for spontaneous transformation of rat mesenchymal stem cells. Stem Cells Dev. 22 (2013), 256–267.
23. [23] He, L., Zhao, F., Zheng, Y., Wan, Y., Song, J., Loss of interactions between p53 and survivin gene in mesenchymal stem cells after spontaneous transformation in vitro. Int. J. Biochem. Cell Biol. 75 (2016), 74–84.
24. [24] Pinilla, S., Alt, E., Abdul Khalek, F.J., Jotzu, C., Muehlberg, F., Beckmann, C., Song, Y.H., Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 284 (2009), 80–85.
25. [25] Luo, J., Lee, S.O., Cui, Y., Yang, R., Li, L., Chang, C., Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2alpha/androgen receptor signals. Oncotarget 6 (2015), 27555–27565.
26. [26] Makinoshima, H., Dezawa, M., Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. FEBS Lett. 583 (2009), 3697–3703.
27. [27] Spaeth, E.L., Dembinski, J.L., Sasser, A.K., Watson, K., Klopp, A., Hall, B., Andreeff, M., Marini, F., Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE, 4, 2009, e4992.
28. [28] Sasser, A.K., Sullivan, N.J., Studebaker, A.W., Hendey, L.F., Axel, A.E., Hall, B.M., Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer. FASEB J., 2007.
29. [29] Mi, Z., Bhattacharya, S.D., Kim, V.M., Guo, H., Talbot, L.J., Kuo, P.C., Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32 (2011), 477–487.
30. [30] Escobar, P., Bouclier, C., Serret, J., Bieche, I., Brigitte, M., Caicedo, A., Sanchez, E., Vacher, S., Vignais, M.L., Bourin, P., Genevieve, D., Molina, F., Jorgensen, C., Lazennec, G., IL-1beta produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. Oncotarget 6 (2015), 29034–29047.
31. [31] Halpern, J.L., Kilbarger, A., Lynch, C.C., Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 308 (2011), 91–99.
32. [32] Wang, J., Wang, Y., Wang, S., Cai, J., Shi, J., Sui, X., Cao, Y., Huang, W., Chen, X., Cai, Z., Li, H., Bardeesi, A.S., Zhang, B., Liu, M., Song, W., Wang, M., Xiang, A.P., Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer. Oncotarget 6 (2015), 42825–42837.
33. [33] Li, W., Zhou, Y., Yang, J., Zhang, X., Zhang, H., Zhang, T., Zhao, S., Zheng, P., Huo, J., Wu, H., Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through secretion of interleukin-8. J. Exp. Clin. Cancer Res., 34, 2015, 52.
34. [34] Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., Nitadori-Hoshino, A., Hoffman, C., Badal, K., Garcia, B.A., Callahan, M.K., Yuan, J., Martins, V.R., Skog, J., Kaplan, R.N., Brady, M.S., Wolchok, J.D., Chapman, P.B., Kang, Y., Bromberg, J., Lyden, D., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18 (2012), 883–891.
35. [35] Shi, S., Zhang, Q., Xia, Y., You, B., Shan, Y., Bao, L., Li, L., You, Y., Gu, Z., Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression. Am. J. Cancer Res. 6 (2016), 459–472.
36. [36] Ji, R., Zhang, B., Zhang, X., Xue, J., Yuan, X., Yan, Y., Wang, M., Zhu, W., Qian, H., Xu, W., Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle 14 (2015), 2473–2483.
37. [37] Barcellos-de-Souza, P., Comito, G., Pons-Segura, C., Taddei, M.L., Gori, V., Becherucci, V., Bambi, F., Margheri, F., Laurenzana, A., Del Rosso, M., Chiarugi, P., Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-beta1. Stem Cells, 2016.
38. [38] McAndrews, K.M., McGrail, D.J., Ravikumar, N., Dawson, M.R., Mesenchymal stem cells induce directional migration of invasive breast cancer cells through TGF-beta. Sci. Report., 5, 2015, 16941.
39. [39] Carnet, O., Lecomte, J., Masset, A., Primac, I., Durre, T., Maertens, L., Detry, B., Blacher, S., Gilles, C., Pequeux, C., Paupert, J., Foidart, J.M., Jerusalem, G., Cataldo, D., Noel, A., Mesenchymal stem cells shed amphiregulin at the surface of lung carcinoma cells in a juxtacrine manner. Neoplasia 17 (2015), 552–563.
40. [40] Berger, L., Shamai, Y., Skorecki, K.L., Tzukerman, M., Tumor specific recruitment and reprogramming of mesenchymal stem cells in tumorigenesis. Stem Cells 34 (2016), 1011–1026.
41. [41] Wang, W., Zhong, W., Yuan, J., Yan, C., Hu, S., Tong, Y., Mao, Y., Hu, T., Zhang, B., Song, G., Involvement of Wnt/beta-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget 6 (2015), 42276–42289.
42. [42] Takam Kamga, P., Bassi, G., Cassaro, A., Midolo, M., Di Trapani, M., Gatti, A., Carusone, R., Resci, F., Perbellini, O., Gottardi, M., Bonifacio, M., Nwabo Kamdje, A.H., Ambrosetti, A., Krampera, M., Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. Oncotarget, 2016.
43. [43] Yulyana, Y., Ho, I.A., Sia, K.C., Newman, J.P., Toh, X.Y., Endaya, B.B., Chan, J.K., Gnecchi, M., Huynh, H., Chung, A.Y., Lim, K.H., Leong, H.S., Iyer, N.G., Hui, K.M., Lam, P.Y., Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol. Ther. 23 (2015), 746–756.
44. [44] Qiao, L., Xu, Z.L., Zhao, T.J., Ye, L.H., Zhang, X.D., Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 269 (2008), 67–77.
45. [45] Attar-Schneider, O., Zismanov, V., Drucker, L., Gottfried, M., Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation. Tumour Biol. 37 (2016), 4755–4765.
46. [46] Khakoo, A.Y., Pati, S., Anderson, S.A., Reid, W., Rovira, M.F.E. II, Nguyen, A.T., Malide, D., Combs, C.A., Hall, G., Zhang, J., Raffeld, M., Rogers, T.B., Stetler-Stevenson, W., Frank, J.A., Reitz, M., Finkel, T., Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203 (2006), 1235–1247.
47. [47] Lee, J.K., Park, S.R., Jung, B.K., Jeon, Y.K., Lee, Y.S., Kim, M.K., Kim, Y.G., Jang, J.Y., Kim, C.W., Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE, 8, 2013, e84256.
48. [48] Lou, G., Song, X., Yang, F., Wu, S., Wang, J., Chen, Z., Liu, Y., Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol., 8, 2015, 122.
49. [49] McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K.R., Buckanovich, R.J., Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J. Clin. Invest. 121 (2011), 3206–3219.
50. [50] Coffman, L.G., Choi, Y.J., McLean, K., Allen, B.L., di Magliano, M.P., Buckanovich, R.J., Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget 7 (2016), 6916–6932.
51. [51] Cuiffo, B.G., Campagne, A., Bell, G.W., Lembo, A., Orso, F., Lien, E.C., Bhasin, M.K., Raimo, M., Hanson, S.E., Marusyk, A., El-Ashry, D., Hematti, P., Polyak, K., Mechta-Grigoriou, F., Mariani, O., Volinia, S., Vincent-Salomon, A., Taverna, D., Karnoub, A.E., MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell 15 (2014), 762–774.
52. [52] Li, H.J., Reinhardt, F., Herschman, H.R., Weinberg, R.A., Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2 (2012), 840–855.
53. [53] Liu, S., Ginestier, C., Ou, S.J., Clouthier, S.G., Patel, S.H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C.G., Jung, Y., Dontu, G., Taichman, R., Wicha, M.S., Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71 (2011), 614–624.
54. [54] Wu, X.B., Liu, Y., Wang, G.H., Xu, X., Cai, Y., Wang, H.Y., Li, Y.Q., Meng, H.F., Dai, F., Jin, J.D., Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-kappaB activation. Sci. Report., 6, 2016, 21420.
55. [55] Tsai, K.S., Yang, S.H., Lei, Y.P., Tsai, C.C., Chen, H.W., Hsu, C.Y., Chen, L.L., Wang, H.W., Miller, S.A., Chiou, S.H., Hung, M.C., Hung, S.C., Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 141 (2011), 1046–1056.
56. [56] Luo, J., Ok Lee, S., Liang, L., Huang, C.K., Li, L., Wen, S., Chang, C., Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 33 (2014), 2768–2778.
57. [57] Yang, Y., Otte, A., Hass, R., Human mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines. Stem Cells Dev. 24 (2015), 1205–1222.
58. [58] Caicedo, A., Fritz, V., Brondello, J.M., Ayala, M., Dennemont, I., Abdellaoui, N., de Fraipont, F., Moisan, A., Prouteau, C.A., Boukhaddaoui, H., Jorgensen, C., Vignais, M.L., MitoCeption as a new tool to assess the effects of mesenchymal stem/stromal cell mitochondria on cancer cell metabolism and function. Sci. Report., 5, 2015, 9073.
59. [59] Martin, F.T., Dwyer, R.M., Kelly, J., Khan, S., Murphy, J.M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F.P., O'Brien, T., Kerin, M.J., Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat., 2010.
60. [60] Iser, I.C., Ceschini, S.M., Onzi, G.R., Bertoni, A.P., Lenz, G., Wink, M.R., Conditioned medium from adipose-derived stem cells (ADSCs) promotes epithelial-to-mesenchymal-like transition (EMT-like) in glioma cells in vitro. Mol. Neurobiol., 2015.
61. [61] Mishra, P.J., Mishra, P.J., Humeniuk, R., Medina, D.J., Alexe, G., Mesirov, J.P., Ganesan, S., Glod, J.W., Banerjee, D., Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68 (2008), 4331–4339.
62. [62] Ohkouchi, S., Block, G.J., Katsha, A.M., Kanehira, M., Ebina, M., Kikuchi, T., Saijo, Y., Nukiwa, T., Prockop, D.J., Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol. Ther. 20 (2012), 417–423.
63. [63] Chowdhury, R., Webber, J.P., Gurney, M., Mason, M.D., Tabi, Z., Clayton, A., Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget 6 (2015), 715–731.
64. [64] Al-toub, M., Vishnubalaji, R., Hamam, R., Kassem, M., Aldahmash, A., Alajez, N.M., CDH1 and IL1-beta expression dictates FAK and MAPKK-dependent cross-talk between cancer cells and human mesenchymal stem cells. Stem Cell Res. Therapy, 6, 2015, 135.
65. [65] Anton, K., Banerjee, D., Glod, J., Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS ONE, 7, 2012, e35036.
66. [66] Ferrand, J., Noel, D., Lehours, P., Prochazkova-Carlotti, M., Chambonnier, L., Menard, A., Megraud, F., Varon, C., Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS ONE, 6, 2011, e19569.
67. [67] Rappa, G., Mercapide, J., Lorico, A., Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am. J. Pathol. 180 (2012), 2504–2515.
68. [68] Quante, M., Tu, S.P., Tomita, H., Gonda, T., Wang, S.S., Takashi, S., Baik, G.H., Shibata, W., Diprete, B., Betz, K.S., Friedman, R., Varro, A., Tycko, B., Wang, T.C., Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19 (2011), 257–272.
69. [69] Tomchuck, S.L., Zwezdaryk, K.J., Coffelt, S.B., Waterman, R.S., Danka, E.S., Scandurro, A.B., Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26 (2008), 99–107.
70. [70] Waterman, R.S., Tomchuck, S.L., Henkle, S.L., Betancourt, A.M., A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE, 5, 2010, e10088.
71. [71] Waterman, R.S., Henkle, S.L., Betancourt, A.M., Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS ONE, 7, 2012, e45590.
72. [72] Griffin, M.D., Elliman, S.J., Cahill, E., English, K., Ceredig, R., Ritter, T., Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?. Stem Cells 31 (2013), 2033–2041.
73. [73] Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noel, D., Jorgensen, C., Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102 (2003), 3837–3844.
74. [74] Ljujic, B., Milovanovic, M., Volarevic, V., Murray, B., Bugarski, D., Przyborski, S., Arsenijevic, N., Lukic, M.L., Stojkovic, M., Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci. Report., 3, 2013, 2298.
75. [75] Nemeth, K., Leelahavanichkul, A., Yuen, P.S., Mayer, B., Parmelee, A., Doi, K., Robey, P.G., Leelahavanichkul, K., Koller, B.H., Brown, J.M., Hu, X., Jelinek, I., Star, R.A., Mezey, E., Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15 (2009), 42–49.
76. [76] Spaggiari, G.M., Abdelrazik, H., Becchetti, F., Moretta, L., MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113 (2009), 6576–6583.
77. [77] Aggarwal, S., Pittenger, M.F., Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005), 1815–1822.
78. [78] Montesinos, J.J., Mora-Garcia Mde, L., Mayani, H., Flores-Figueroa, E., Garcia-Rocha, R., Fajardo-Orduna, G.R., Castro-Manrreza, M.E., Weiss-Steider, B., Monroy-Garcia, A., In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Stem Cells Dev. 22 (2013), 2508–2519.
79. [79] Razmkhah, M., Jaberipour, M., Erfani, N., Habibagahi, M., Talei, A.R., Ghaderi, A., Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-beta1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response?. Cell. Immunol. 266 (2011), 116–122.
80. [80] Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., Van den Eynde, B.J., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003), 1269–1274.
81. [81] Meisel, R., Zibert, A., Laryea, M., Gobel, U., Daubener, W., Dilloo, D., Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004), 4619–4621.
82. [82] Maby-El Hajjami, H., Ame-Thomas, P., Pangault, C., Tribut, O., DeVos, J., Jean, R., Bescher, N., Monvoisin, C., Dulong, J., Lamy, T., Fest, T., Tarte, K., Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res. 69 (2009), 3228–3237.
83. [83] Han, Z., Tian, Z., Lv, G., Zhang, L., Jiang, G., Sun, K., Wang, C., Bu, X., Li, R., Shi, Y., Wu, M., Wei, L., Immunosuppressive effect of bone marrow-derived mesenchymal stem cells in inflammatory microenvironment favours the growth of B16 melanoma cells. J. Cell. Mol. Med. 15 (2011), 2343–2352.
84. [84] Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.R., Roberts, A.I., Zhang, L., Zheng, B., Wen, T., Han, Y., Rabson, A.B., Tischfield, J.A., Shao, C., Shi, Y., CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 11 (2012), 812–824.
85. [85] Guilloton, F., Caron, G., Menard, C., Pangault, C., Ame-Thomas, P., Dulong, J., De Vos, J., Rossille, D., Henry, C., Lamy, T., Fouquet, O., Fest, T., Tarte, K., Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119 (2012), 2556–2567.
86. [86] Patel, S.A., Dave, M.A., Bliss, S.A., Giec-Ujda, A.B., Bryan, M., Pliner, L.F., Rameshwar, P., Treg/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells. J. Cancer Stem Cell Res., 2014, 2014.
87. [87] Daverey, A., Drain, A.P., Kidambi, S., Physical intimacy of breast cancer cells with mesenchymal stem cells elicits trastuzumab resistance through Src activation. Sci. Report., 5, 2015, 13744.
88. [88] Skolekova, S., Matuskova, M., Bohac, M., Toro, L., Durinikova, E., Tyciakova, S., Demkova, L., Gursky, J., Kucerova, L., Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell Commun. Sign., 14, 2016, 4.
89. [89] Teng, I.W., Hou, P.C., Lee, K.D., Chu, P.Y., Yeh, K.T., Jin, V.X., Tseng, M.J., Tsai, S.J., Chang, Y.S., Wu, C.S., Sun, H.S., Tsai, K.D., Jeng, L.B., Nephew, K.P., Huang, T.H., Hsiao, S.H., Leu, Y.W., Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res. 71 (2011), 4653–4663.
90. [90] Ono, M., Kosaka, N., Tominaga, N., Yoshioka, Y., Takeshita, F., Takahashi, R.U., Yoshida, M., Tsuda, H., Tamura, K., Ochiya, T., Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Sign., 7, 2014, ra63.
91. [91] Bliss, S.A., Sinha, G., Sandiford, O., Williams, L., Engelberth, D.J., Guiro, K., Isenalumhe, L.L., Greco, S.J., Ayer, S., Bryan, M., Kumar, R., Ponzio, N., Rameshwar, P., Mesenchymal stem cell-derived exosomes stimulates cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res., 2016.
92. [92] Roodhart, J.M., Daenen, L.G., Stigter, E.C., Prins, H.J., Gerrits, J., Houthuijzen, J.M., Gerritsen, M.G., Schipper, H.S., Backer, M.J., van Amersfoort, M., Vermaat, J.S., Moerer, P., Ishihara, K., Kalkhoven, E., Beijnen, J.H., Derksen, P.W., Medema, R.H., Martens, A.C., Brenkman, A.B., Voest, E.E., Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 20 (2011), 370–383.
93. [93] Sugrue, T., Brown, J.A., Lowndes, N.F., Ceredig, R., Multiple facets of the DNA damage response contribute to the radioresistance of mouse mesenchymal stromal cell lines. Stem Cells 31 (2013), 137–145.
94. [94] Beckermann, B.M., Kallifatidis, G., Groth, A., Frommhold, D., Apel, A., Mattern, J., Salnikov, A.V., Moldenhauer, G., Wagner, W., Diehlmann, A., Saffrich, R., Schubert, M., Ho, A.D., Giese, N., Buchler, M.W., Friess, H., Buchler, P., Herr, I., VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 99 (2008), 622–631.
95. [95] Wang, H.H., Cui, Y.L., Zaorsky, N.G., Lan, J., Deng, L., Zeng, X.L., Wu, Z.Q., Tao, Z., Guo, W.H., Wang, Q.X., Zhao, L.J., Yuan, Z.Y., Lu, Y., Wang, P., Meng, M.B., Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. Cancer Lett. 375 (2016), 349–359.
96. [96] Zhu, W., Huang, L., Li, Y., Zhang, X., Gu, J., Yan, Y., Xu, X., Wang, M., Qian, H., Xu, W., Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 315 (2012), 28–37.
97. [97] Huang, W.H., Chang, M.C., Tsai, K.S., Hung, M.C., Chen, H.L., Hung, S.C., Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 32 (2013), 4343–4354.
98. [98] Kozlowski, L., Zakrzewska, I., Tokajuk, P., Wojtukiewicz, M.Z., Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med. Bialymst 48 (2003), 82–84.
99. [99] Ho, I.A., Toh, H.C., Ng, W.H., Teo, Y.L., Guo, C.M., Hui, K.M., Lam, P.Y., Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31 (2013), 146–155.
100. [100] Roccaro, A.M., Sacco, A., Maiso, P., Azab, A.K., Tai, Y.T., Reagan, M., Azab, F., Flores, L.M., Campigotto, F., Weller, E., Anderson, K.C., Scadden, D.T., Ghobrial, I.M., BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123 (2013), 1542–1555.